Compare Summit Therapeutics Inc (SMMT) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Vital Farms Inc — how do they compare? Summit Therapeutics Inc trades at $17.45 (market cap $13.71B), while Vital Farms Inc trades at $9.36 (market cap $405.27M). The key difference: Summit Therapeutics Inc is far larger — about 33.8× Vital Farms Inc's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Vital Farms Inc for 14 Days on average.
| SMMT | VITL | |
|---|---|---|
Market Cap | $13.71B | $405.27M |
Volume | 6,173,057 | 1,810,837 |
Sector | Health | Consumer Staples |
52-Week High | $26.38 | $43.68 |
52-Week Low | $12.43 | $8.28 |
Typical Hold Time | 16 Days | 14 Days |
Enterprise Value | $13.04B | $492.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Vital Farms (VITL) trades at $9.36, up 1.3% on the day, amid a challenging period marked by recent earnings misses and a bearish technical signal. The stock shows weak profitability with a net margin of 0.02% in 2026, though valuation ratios like P/E of 11.77 and P/S of 0.55 appear modest. Recent news highlights strategic review speculation and institutional buying interest, providing some positive sentiment against operational headwinds.
The outlook remains cautious due to earnings volatility and cash flow concerns, but analyst consensus is bullish with a $13.11 price target. Key risks include egg pricing pressure and execution challenges, while potential upside hinges on strategic moves and demand recovery for pasture-raised eggs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
